Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neumora Therapeutics, Inc. - Common Stock
(NQ:
NMRA
)
1.740
+0.050 (+2.96%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neumora Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
NMRA Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc. (NMRA)
February 15, 2025
RADNOR, PA - February 15, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora...
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
NMRA Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc. (NMRA)
February 15, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Kessler Topaz Meltzer & Check, LLP Class Action Announcement NMRA: A Securities Fraud Class Action Lawsuit Was Filed Against Neumora Therapeutics, Inc. (NMRA)
February 14, 2025
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
February 14, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
February 13, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Class Action Announcement for Neumora Therapeutics, Inc. (NMRA): Kessler Topaz Meltzer & Check, LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc.
February 13, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Class Action Announcement for Neumora Therapeutics, Inc. (NMRA): Kessler Topaz Meltzer & Check, LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc.
February 13, 2025
RADNOR, PA - February 13, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Neumora Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NMRA
February 13, 2025
From
Robbins LLP
Via
GlobeNewswire
Neumora Therapeutics Announces Leadership Transition
February 13, 2025
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
NMRA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 12, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 12, 2025
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 12, 2025
From
The Schall Law Firm
Via
Business Wire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
February 11, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces That Neumora Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 08, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
February 06, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
February 06, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc. – NMRA
February 06, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
January 03, 2025
Via
Benzinga
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
January 02, 2025
From
DJS Law Group
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 02, 2025
Via
Benzinga
Crude Oil Surges 2%; Tesla Shares Plummet
January 02, 2025
Via
Benzinga
Exposures
Fossil Fuels
Nasdaq Dips Over 100 Points; Unity Software Shares Jump
January 02, 2025
Via
Benzinga
Dow Surges Over 300 Points; US Initial Jobless Claims Decline
January 02, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
January 02, 2025
The company said it plans to investigate a positive signal from female patients.
Via
Investor's Business Daily
Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
January 02, 2025
Via
Benzinga
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
January 02, 2025
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and updates are anticipated.
Via
Benzinga
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
January 02, 2025
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
December 18, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.